Spectrum Pharmaceuticals Inc., an Irvine drug maker, said Tuesday a judge awarded it $4.3 million from an ongoing dispute with Seattle-based Cell Therapeutics Inc.
The two companies formed a joint venture in 2008 called RIT Oncology LLC to sell Zevalin, a cancer drug. Cell Therapeutics sold its 50% stake to Spectrum in February for $18 million.
The two went to court over joint venture expenses.
Spectrum said in a release that the arbitration award, which is final and binding, calls for releasing $3.5 million through an escrow account and for Cell Therapeutics to pay $776,454 with a wire transfer.
Spectrum is awaiting word from the Food and Drug Administration on expanded marketing for Zevalin, a decision that? due in July. Zevalin is used to treat non-Hodgkin’s lymphoma, which affects the lymph and immune systems.
